Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Peripheral Biomarker Based Combinatorial Early Diagnostics for Dementia

Project description

AI-driven diagnostic protocol for early Alzheimer's disease detection

Dementia is a devastating disease that affects older people. It is one of the greatest challenges of the contemporary world and a social issue highlighted by the UN Sustainable Development Goals and Horizon Europe. With the support of the Marie Skłodowska-Curie Actions programme, the CombiDiag project will develop an AI-driven diagnostic protocol using peripheral biomarkers to detect Alzheimer’s disease (AD) early. It will train a new generation of researchers while studying minimally invasive biomarkers in body fluids and digital markers of speech and motor function. The project will enhance researchers’ skills under the Vitae Researcher Development Framework. The results will lead to improved early diagnosis and treatment strategies for AD.

Objective

CombiDiag DN aims to develop an AI-data-driven peripheral biomarker based combinatorial diagnostic protocol for early stages of Alzheimers disease (AD), a major form of dementia, and to train a new generation of fellows for this interdisciplinary field. Dementia, a devastating disease of older age, is the challenge of our lifetime and one of the Societal Challenges listed by the UN Sustainable Development Goals and Horizon Europe. CombiDiag responds to this challenge to establish a much-needed DN to carry out an integrated study of minimally invasive and cost-effective peripheral biomarkers, including body fluid markers from blood, urine and saliva, and digital markers from speech, motor functions and sleep for developing the combinatorial early AD diagnostics. The consortium comprises nine academic and eight non-academic institutions across Europe, USA, Canada, and China. It synergises leading academic and industrial experts worldwide to build a triple-i research and training platform for the training of a new generation of Fellows to take early AD diagnostic research to a new level. Fellows will be trained under the Vitae Researcher Development Framework innovatively combined with the CombiDiag platform for triple-i scientific and transferable skills as well as personal quality, creative thinking, and business mind-set. The DN has a highly innovative research programme for the discovery of peripheral AD biomarkers, detection techniques, AI/data driven technology, clinical validation, and integration into trial designs. The advances in CombiDiag research will enable a case finding tool at primary care level for helping achieve improved drug discoveries, disease-modifying treatments, preventive strategies and care provision for AD. CombiDiag will deliver 10 highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2021-DN-01

See all projects funded under this call

Coordinator

UNIVERSITATSMEDIZIN ROSTOCK
Net EU contribution
€ 260 539,20
Address
SCHILLINGALLEE 35
18055 Rostock
Germany
Region
Mecklenburg-Vorpommern Mecklenburg-Vorpommern Rostock, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (7)

Partners (14)